T. Rowe Price Investment Management
BCAX

T. Rowe Price Investment Management’s Bicara Therapeutics BCAX Stock Holding History

T. Rowe Price Investment Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$131M Buy
6,605,780
+3,369,185
+104% +$58M 0.09% 212
2025
Q4 		$54.5M Buy
3,236,595
+2,771,868
+596% +$47.3M 0.03% 350
2025
Q3 		$7.34M Buy
+464,727
New +$5.2M ﹤0.01% 568

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $173M AUM

T. Rowe Price Investment Management's BCAX Position: Q1 2026 in Review

T. Rowe Price Investment Management increased its Bicara Therapeutics (BCAX) stake by 104% in Q1 2026, buying an estimated $58M and bringing the position to 6,605,780 shares worth $131M. The position accounts for 0.09% of the portfolio, ranked #212.

T. Rowe Price Investment Management first reported a position in BCAX in Q3 2025 and has held it in 3 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • T. Rowe Price Investment Management held 6,605,780 shares of Bicara Therapeutics worth $131M as of Q1 2026.
  • T. Rowe Price Investment Management bought 3,369,185 Bicara Therapeutics shares in Q1 2026, an estimated $58M.
  • Bicara Therapeutics made up 0.09% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #212 holding.
  • T. Rowe Price Investment Management first reported a position in Bicara Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.